A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Patient of Anemia in Chronic Renal Failure With Hemodialysis Clinical Trial

Official title:

A Multicenter, Randomized, Single-blind, Active Comparator Controlled Phase 2 Clinical Study on the Effectiveness, Safety and Pharmacokinetics of Pegerythropoietin Injection (RD01) in Different Medication Schemes for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04231292
• Other study ID #: SZSBE-RD01-HD-II-01
• Status: Recruiting
• Phase: Phase 2
• Start date: March 1, 2020
• Est. completion date: December 31, 2022

Study information

• Verified date: January 2020
• Source: Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd
• Contact: Gengru Jiang, Medical PhD
• Phone: 13816238339
• Email: jianggeng-ru[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A multicenter randomized, single blind, active comparator controlled phase 2 study which is to evaluate the effectiveness, safety and the PK/PD characteristics of different doses, frequencies and routes of pegerythropoietin Injection (RD01) as maintenance therapy in the treatment of anemia in chronic renal failure patients with hemodialysis

Description:

This trial is a multicenter randomized, single blind, active comparator controlled phase 2 study. The study is divided into two stages. The first stage lasts for 18 weeks, and is divided into fixed dose period (day 1~ 6th week ) and dose adjustment period (7th ~ 18th week). The second stage lasts for 28 weeks, and is also divided into dose adjustment period (19th ~ 38th week) and evaluation period (39th ~ 46th week).

Patients are randomly assigned to seven study groups in the first stage. Of all these seven groups, six groups are: Group A (0.8μg/kg RD01, once every two weeks, subcutaneous injection, for 18 weeks)、Group B (1.2μg/kg RD01, once every two weeks, subcutaneous injection, for 18 weeks)、Group C (1.6μg/kg RD01, once every two weeks, subcutaneous injection, for 18 weeks)、 Group D (0.8ug/kg RD01, once every two weeks, intravenous injection, for 18 weeks)、Group E ( 150 IU/kg rHuEPO, once a week, subcutaneous injection, for 18 weeks )、Group F (8μl /kg placebo, once every two weeks, for 6 weeks; then 150 IU/kg rHuEPO, once a week, subcutaneous injection, 7th ~ 18th week ).

At the beginning of the second stage, some patients in these six goups need to be be randomized again. Of which patients in Group A、B、C are randomly assigned to Group a ( RD01, once every two weeks, subcutaneous injection, 19th ~ 46th week )、Group b (RD01, once every four weeks, subcutaneous injection, 19th ~ 46th week)、Group c (RD01, once every six weeks, subcutaneous injection, 19th ~ 46th week); Patients in Group D enter directly to Group d (RD01, once every four weeks, intravenous injection, 19th ~ 46th week); Patients in Group E and F are randomly assigned to Group e (rHuEPO once a week, intravenous injection, 19th ~ 46th week ) and Group f (rHuEPO once a week, subcutaneous injection, 19th ~ 46th week). The starting dose of the second stage for individual patient in all groups refers to the weekly dose at the end of the first stage .

During the whole study period, all patients in six groups are not allowed to adjust dosage in the first 6 weeks, while in the remaining trial period dosage adjustment was allowed once every two weeks if necessary.

There is a special Group G (1.6μg/kg RD01, once every four weeks, subcutaneous injection, Day 1 ~ 28th week), all patients are allowed to adjust dosage during the whole 28 weeks.

This phase 2 study is to evaluate the effectiveness, safety and the PK/PD characteristics of different doses, frequencies and routes of pegerythropoietin Injection (RD01) as maintenance therapy in the treatment of anemia in chronic renal failure patients with hemodialysis

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 105
• Est. completion date: December 31, 2022
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with chronic renal failure who are undergoing maintenance hemodialysis for at least 12 weeks;

• 18 = age = 75 years of age, male or female;

• Patients who have received short-acting EPO treatment and meets the treatment standard (hemoglobin 100 ~ 120 g / L). The mean Hb value in the screening period (at least two weeks apart ) is within the range of 100 ~ 120 g / L (both ends). The difference is less than 10g / L;

• Evaluation of iron status during the screening period, transferrin saturation (TSAT) =20% or serum ferritin (SF) =200 µg / L;

• Evaluation of dialysis adequacy during the screening period, with SpKt / V=1.2 or URR=65%;

• Subjects agree to use reliable contraceptives from the screening period to within 6 months after the last medication

• Sign the informed consent.

Exclusion Criteria:

• Patients who have received or plan to have a kidney transplant during the study period

• Except of renal anemia, there are other diseases that cause chronic anemia (such as sickle cell anemia, myelodysplastic syndrome, hematological malignancies, myeloma, hemolytic anemia, pure red blood cell aplastic anemia)

• Patients with acute or chronic blood loss (such as upper gastrointestinal bleeding) in the past 3 months or patients who have undergone surgery with extensive bleeding, or patients who plan to undergo surgery during the study period

• Patients with coagulation dysfunction (time to activate partial thromboplastin> 1.5 times the upper limit of normal value)

• The following circumstances (including but not limited to) during the screening, investigators evaluated that it is not suitable for enrollment:

1. Abnormal liver function (aspartate aminotransferase or alanine aminotransferase is more than 3 times the upper limit of normal value);

2. Patients who were positive for Hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBeAg), HIV antibody (HIV-Ab), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum antibody;

• Patients with severe secondary hyperparathyroidism (iPTH> 1000 ng / L);

• Patients with severe hypertension and poor control of blood pressure (systolic blood pressure> 180 mmHg or diastolic blood pressure> 100 mmHg)

• Patients with severe thromboembolic disease

• People with severe cardio-cerebral vascular disease (excluding luminal infarction), severe or unstable coronary artery disease, heart failure (NYHA III or IV) or myocardial infarction or stroke within 3 months

• Patients with malignant tumors (excluding non-melanoma skin cancer or resected cancer in situ)

• People with a history of severe allergies (including drug allergies), allergies to erythropoietin, or allergic to any component of the test drug (such as human serum albumin)

• People with severe infection who are receiving systemic antibiotics

• Patients who have received androgen therapy or blood transfusion therapy within the last 8 weeks;

• Participated in other new drug clinical trials as a subject within 3 months or the withdrawal time was shorter than the 5 half-life of the test drug at the time of enrollment (whichever is the longest);

• Patients with a history of seizures

• Pregnant and lactating women

• Alcohol, drug or drug addicts

• Other situations that the researcher believes may affect validity judgment or are not suitable for participation.

Related Conditions & MeSH terms

• Anemia
• Kidney Failure, Chronic
• Patient of Anemia in Chronic Renal Failure With Hemodialysis
• Renal Insufficiency
• Renal Insufficiency, Chronic

Intervention

Drug:
• RD01
RD01 is a PEGylated recombinant human erythropoietin with the same biological effects as natural erythropoietin
• Recombinant Human Erythropoiesis Injection (CHO cell)
rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
• placebo
placebo

Locations

Country	Name	City	State
China	Renal Rheumatology and Immunology department Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shengzhen Sciprogen Bio-pharmaceutical Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary efficacy index : The change of hemoglobin concentration of experimental group from baseline to the end of 4th and 6th week		Day 1~4th week & Day 1~6th week
Primary	Primary efficacy index: The difference of hemoglobin concentration between the experimental group and the placebo group at the end of 4th and 6th week;		Day 1~4th week & Day 1~6th week
Primary	Primary efficacy index: hemoglobin concentration change from baseline to the end of first stage	The amount of change in hemoglobin concentration from baseline to the end of the first stage	Day 1~18th week
Primary	Primary efficacy index: hemoglobin concentration change from baseline to the evaluation periods in the second stage (39th ~46th week)	The amount of change in hemoglobin concentration from baseline to the evaluation periods in the second stage (39th ~46th week).	Day 1~ evaluation periods (39th ~46th week)
Secondary	Secondary efficacy index: the optimal dosage	The optimal dosage of the subjects at the end of the first stage and the evaluation period (39th ~46th week) in the second stage	the end of 18th week & 39th ~46th week
Secondary	Secondary efficacy index: maintenance rate	the proportion of subjects whose average Hb concentration remain within the target range during the evaluation period	39th-46th week
Secondary	Secondary efficacy index : Proportion of subjects with unstable Hb during the evaluation period		39th-46th week
Secondary	Secondary efficacy index: proportion of times of Hb remains within the target range	the proportion of times the measured Hb concentration remains within the target range during the evaluation period;	39th-46th week
Secondary	Secondary efficacy index: EPO dose conversion coefficient of RD01	EPO dose conversion factor for subjects at the end of the first stage and evaluation periods in the second stage	end of 18th week & 39th ~46th week
Secondary	Safety indicator: adverse events	the type, proportion and severity of adverse events	for 46 weeks
Secondary	Immunogenicity indicator: incidence of anti-RD01 antibodies	incidence of anti-RD01 antibodies	for 46 weeks
Secondary	Maximum Plasma Concentration (Cmax)	the Cmax of RD01 in patients with long-term medication.	for 46 weeks
Secondary	Area Under the Curve (AUC)	the AUC of RD01 in patients with long-term medication.	for 46 weeks